Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 23;34(4):367-372.
doi: 10.4103/tcmj.tcmj_78_22. eCollection 2022 Oct-Dec.

Gene therapy in hereditary retinal dystrophy

Jia-Ying Chien  1 , Shun-Ping Huang  1   2   3
Affiliations
Review

Gene therapy in hereditary retinal dystrophy

Jia-Ying Chien et al. Tzu Chi Med J. .

Abstract

Hereditary retinal dystrophies (HRDs), such as retinitis pigmentosa, Leber's congenital amaurosis (LCA), Usher syndrome, and retinoschisis, are a group of genetic retinal disorders exhibiting both genetic and phenotypic heterogeneity. Symptoms include progressive retinal degeneration and constricted visual field. Some patients will be legal or completely blind. Advanced sequencing technologies improve the genetic diagnosis of HRD and lead to a new era of research into gene-targeted therapies. Following the first Food and Drug Administration approval of gene augmentation therapy for LCA caused by RPE65 mutations, multiple clinical trials are currently underway applying different techniques. In this review, we provide an overview of gene therapy for HRD and emphasize four distinct approaches to gene-targeted therapy that have the potential to slow or even reverse retinal degeneration: (1) viral vector-based and nonviral gene delivery, (2) RNA-based antisense oligonucleotide, (3) genome editing by the Clustered Regularly Interspaced Short Palindromic Repeat/cas9 system, and (4) optogenetics gene therapy.

Keywords: Antisense oligonucleotides; Clustered Regularly Interspaced Short Palindromic Repeat/cas system; Gene therapy; Optogenetics; Retinal dystrophy.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Summary diagram of gene-targeted therapies for hereditary retinal dystrophies. Recent developments in various gene-targeted therapies, including viral or nonviral based gene delivery, optogenetics, genomic editing, or RNA-based therapeutics, could offer potential treatments for HRD patients. HRD: Hereditary retinal dystrophies
See this image and copyright information in PMC

References

    1. Carrigan M, Duignan E, Malone CP, Stephenson K, Saad T, McDermott C, et al. Panel-based population next-generation sequencing for inherited retinal degenerations. Sci Rep. 2016;6:33248. - PMC - PubMed
    1. Ge Z, Bowles K, Goetz K, Scholl HP, Wang F, Wang X, et al. NGS-based Molecular diagnosis of 105 eyeGENE(®) probands with Retinitis Pigmentosa. Sci Rep. 2015;5:18287. - PMC - PubMed
    1. Bravo-Gil N, Méndez-Vidal C, Romero-Pérez L, González-del Pozo M, Rodríguez-de la Rúa E, Dopazo J, et al. Improving the management of Inherited Retinal Dystrophies by targeted sequencing of a population-specific gene panel. Sci Rep. 2016;6:23910. - PMC - PubMed
    1. Birtel J, Gliem M, Mangold E, Müller PL, Holz FG, Neuhaus C, et al. Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa. PLoS One. 2018;13:e0207958. - PMC - PubMed
    1. Salmaninejad A, Motaee J, Farjami M, Alimardani M, Esmaeilie A, Pasdar A. Next-generation sequencing and its application in diagnosis of retinitis pigmentosa. Ophthalmic Genet. 2019;40:393–402. - PubMed